Recently, Tyra Biosciences announced that their lead drug candidate, Tyra-300, has gained significant attention in oncology and rare genetic disease treatment. 

The backbone of this drug features a 2,6-diazaspiro[3.3]heptane fragment. To foster further research, we have developed a set of Building Blocks derived from this unique moiety!

Tyra-300 is an FGFR3-selective inhibitor designed to target mutations linked to cancer progression and achondroplasia, a common genetic disorder leading to restricted growth. This compound is currently being studied in clinical trials aimed at treating metastatic urothelial carcinoma as well as skeletal dysplasias. The FDA has granted Rare Pediatric Disease (RPD) Designation to Tyra-300, for its potential to treat achondroplasia, highlighting its promise in addressing the severe skeletal complications caused by mutations in the FGFR3 gene.

Interested or have any questions? Contact us at sales@chem-space.com.